ADS rules out early combo therapy in type 2

The Australian Diabetes Society has rejected calls to revamp guidelines on initial combination therapy for patients with type 2 diabetes.   

The debate was first sparked by two presentations at the 2016 European Association for the Study of Diabetes (EASD) conference which argued early initiation of combination therapy would lead to improved HbA1c and bodyweight outcomes for patients.

The American Association of Clinical